Related Experiment Video
Updated: May 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Equity in statin use in New Zealand
Pauline Norris1, Simon Horsburgh2, Gordon Becket3
1School of Pharmacy, University of Otago, PB 56, Dunedin, New Zealand. pauline.norris@otago.ac.nz.
Introduction:
Preventive medications such as statins are used to reduce cardiovascular risk. There is some evidence to suggest that people of lower socioeconomic position are less likely to be prescribed statins. In New Zealand, Maori have higher rates of cardiovascular disease.
Aim:
This study aimed to investigate statin utilisation by socioeconomic position and ethnicity in a region of New Zealand.
Methods:
This was a cross-sectional study in which data were collected on all prescriptions dispensed from all pharmacies in one city during 2005/6. Linkage with national datasets provided information on patients' age, gender and ethnicity. Socioeconomic position was identified using the New Zealand Index of Socioeconomic Deprivation 2006.
Results:
Statin use increased with age until around 75 years. Below age 65 years, those in the most deprived socioeconomic areas were most likely to receive statins. In the 55-64 age group, 22.3% of the most deprived population received a statin prescription (compared with 17.5% of the mid and 18.6% of the least deprived group). At ages up to 75 years, use was higher amongst Maori than non-Maori, particularly in middle age, where Maori have a higher risk of cardiovascular disease. In the 45-54 age group, 11.6% of Maori received a statin prescription, compared with 8.7% of non-Maori.
Discussion:
Statin use approximately matched the pattern of need, in contrast to other studies which found under-treatment of people of low socioeconomic position. A PHARMAC campaign to increase statin use may have increased use in high-risk groups in New Zealand.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

